The document, which was designed to help guide both interventional cardiology trainees and program directors, was also endorsed by several other industry societies. 

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

American Heart Association President Michelle Albert, MD, talked to us about about how to address health inequities in cardiology departments.

Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic. 

Post-operative atrial fibrillation was once viewed as a fairly insignificant issue, but more recent research suggests it can increase a patient’s risk of multiple adverse events. 

The team hopes its findings can lead to significant progress in the war against fatty plaques.

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital, discussed the cases of AFib being seen in long-COVID patients.

In this new video, pediatric cardiologists discuss some of the long-term issues associated with multisystem inflammatory syndrome in children (MIS-C), a rare disease linked to COVID-19.